Our Pipeline
| Indication | Compound | Stage | Progress | Icon |
|---|---|---|---|---|
| Glaucoma, Neovascular Glaucoma, Proliferative Diabetic Retinopathy | EIR-1003 | Preclinical |
Discovery → Preclinical
|
 |
| Uveal Melanoma | EIR-1003 | Preclinical |
Discovery → Preclinical
|
|
| Stargardt Disease | EIR-0205 | Preclinical |
Discovery → Preclinical
|
|
Targeted Modulation of the Ephrin Receptor
EIR-1003 is a first-in-class small molecule with neuroprotective activity that has shown positive results in animal models of glaucoma, neuroinflammation and neurodegeneration.
Designed to block pathogenic ephrin signaling, EIR-1003 antagonizes both EphA and EphB receptors to:
Prevent retinal ganglion cell death
Restore axonal integrity
Reduce inflammation and synaptic instability
EIR-1003 has been shown to increase regeneration of retinal ganglion cell axonal projections distal to the optic nerve head in animal models.
Research & Innovation
A Platform Built for Vision and Beyond
Ephrin receptor biology is not eye-specific. Ephrin receptor signaling pathways are active in:
CNS neurodegeneration and neuroinflammation (e.g., Alzheimer’s, Parkinson’s diseases)
Cancer - cell motility and metastasis
Vascular patterning and endothelial cell function
Neovascularization and angiogenesis
We are developing a broad therapeutic platform targeting the Ephrin receptor based on a pipeline in a mechanism drug development strategy with applications across neurodegenerative disease, proliferative disease, neovascular disease, and cancer.